Cyclo Therapeutics, Inc. - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES

Ticker Exchange SIC # Website Latest Ticker
CYTH Nasdaq 5122 cyclotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyclo Therapeutics, Inc.

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025 - Jan 14th, 2025 1:05 pm
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results - Dec 11th, 2024 12:00 pm
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 14th, 2024 1:05 pm
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - Nov 7th, 2024 12:14 am
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - Oct 21st, 2024 12:00 pm
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) - Sep 5th, 2024 1:05 pm
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement - Aug 22nd, 2024 10:50 am
Cyclo Therapeutics Second Quarter 2024 Earnings: Misses Expectations - Aug 17th, 2024 12:55 pm
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Aug 15th, 2024 1:00 pm
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office - Jul 29th, 2024 1:05 pm
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 - Jun 25th, 2024 1:25 pm
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results - Jun 14th, 2024 8:01 pm
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 - May 30th, 2024 1:00 pm
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 16th, 2024 12:05 pm
Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock - Apr 10th, 2024 12:13 pm
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - Mar 18th, 2024 1:05 pm
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease - Mar 14th, 2024 1:34 pm
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results - Mar 13th, 2024 9:04 pm
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office - Jan 29th, 2024 2:15 pm